Compare · CYAN vs DFTX
CYAN vs DFTX
Side-by-side comparison of Cyanotech Corporation (CYAN) and Definium Therapeutics Inc. (DFTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CYAN and DFTX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $4.56B, about 261.9x CYAN ($17.4M).
- DFTX has hit the wire 8 times in the past 4 weeks while CYAN has been quiet.
- DFTX has more recent analyst coverage (6 ratings vs 0 for CYAN).
- Company
- Cyanotech Corporation
- Definium Therapeutics Inc.
- Price
- $0.45-6.43%
- $41.77-3.99%
- Market cap
- $17.4M
- $4.56B
- 1M return
- -
- -5.55%
- 1Y return
- -
- +345.97%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 0
- 8
- Recent ratings
- 0
- 6
Cyanotech Corporation
Cyanotech Corporation engages in the cultivation, production, and sale of natural products derived from microalgae for the health and human nutrition markets worldwide. Its products include BioAstin Hawaiian Astaxanthin, a dietary antioxidant, which is used as a human dietary supplement and dietary ingredient to support and maintain the body's natural inflammatory response, enhance skin, and support eye, joint, and immune health; and Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement that is used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. The company sells its products as packaged consumer products through distributors, retailers, and online channels, and direct to consumers, as well as in bulk form to manufacturers, formulators, and distributors. Cyanotech Corporation was incorporated in 1983 and is headquartered in Kailua-Kona, Hawaii.
Latest CYAN
- SEC Form 15-12G filed by Cyanotech Corporation
- Amendment: SEC Form SC 13E3/A filed by Cyanotech Corporation
- Amendment: SEC Form SC 13E3/A filed by Cyanotech Corporation
- SEC Form SC 13E3 filed by Cyanotech Corporation
- SEC Form 10-Q filed by Cyanotech Corporation
- Cyanotech Reports Financial Results for the Second Quarter of Fiscal 2026
- SEC Form 4 filed by CFO, VP Fin & Admin, Treasurer Miyashiro Jennifer A.S.
- SEC Form 3 filed by new insider Miyashiro Jennifer A.S.
- Director Mulder David M was granted 50,000 units of Cyanotech Corporation Common Stock, increasing direct ownership by 33% to 203,468 units (SEC Form 4)
- Director Vied David L was granted 50,000 units of Cyanotech Corporation Common Stock, increasing direct ownership by 29% to 225,138 units (SEC Form 4)
Latest DFTX
- Definium Therapeutics Announces New Employee Inducement Grants
- Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
- Wells Fargo initiated coverage on Definium Therapeutics with a new price target
- A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening
- Definium Therapeutics Announces New Employee Inducement Grants
- Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
- Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology
- New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)
- Definium Therapeutics Announces New Employee Inducement Grants
- Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity